What is Radiomics?
Turning medical images into data
Radiomics Pipeline
The radiomics pipeline extracts quantitative features from medical images to uncover hidden patterns, enabling personalized treatment and data-driven decisions.
Our Services
radiomics.bio delivers comprehensive image-based insights for your clinical trial
What is Radiomics?
Radiomics is a processing workflow that extracts quantitative biomarker measurements from medical imaging aimed at supporting clinical decision making.
Revealing hidden information
Radiomics explores the hidden information in standard of care medical images such as CT, PET and MRI to quantify and unravel the underlying biological effects of lesions not visible by the naked eye
Providing quantitative insights
Radiomics can be more comprehensive, quantitative and insightful than standard imaging analysis methodologies such as RECIST.
Predicting Clinical Outcome
Radiomics aims to harness the full power of medical imaging to assess, measure and predict clinical outcomes such as prognosis and response to treatment.
01
Data Collection & Organisation
02
Quality
Assessment
03
3D
Segmentation
04
Annotation & tracking
05
Quantification
06
Statistical description & AI modeling
How we can help you
Radiomics in oncology
Diagnosis
Detection and classification of tumours, benign vs malignant lesions
Histology Prediction
Staging and tumor subtypes
Genetic expression
Single and multiple lesion cancer biology, biomarkers for therapy decision making
Response Prediction
Therapy-induced changes, classification of responders vs non responders
Immune-related expression
Single and multiple lesion cancer biology, biomarkers for therapy decision making
Prognosis
After surgical/non-surgical intervention Overall survival
Radiomics in Clinical Trials
Radiomics can add value to clinical trials by offering new insights into key clinical trial questions
Phase 1
Detecting early signs
Is the drug having an effect on specific lesions?
What are the most promising indications to take forward?
Is the drug safe?
How does response change with escalation?
Phase 2
Optimising clinical trials
Is the mechanism of action aligned with my expectations?
Are there response differences between different treatment arms?
What is the phenotype of responders?
Phase 3
Powering for success
How can treatment insights be used to ensure a fair and unbiased trials?
Is there a way to predict response at baseline or at early stages?
Is there an opportunity for an imaging companion diagnostic to optimise impact?
Post-market
Going beyond
What additional evidence can be generated for the treatment?
Can the insights derived from the treatment be applied to other indications?
Can the treatment protocol be optimised?
Ikonics® Platform
End-to-end radiomics with Ikonics® — our all-in-one platform for efficient, accurate, and clinically relevant image analysis.
Ikonics® streamlines the entire radiomics pipeline, from data acquisition to feature quantification. With secure storage, AI-driven segmentation, and real-time tracking, it ensures accuracy, efficiency, and reproducible results for clinical decision-making.
Explore our Ikonics® Platform
Our Services
What can we do for you?
Beyond the typical services of an imaging CRO, radiomics.bio positions itself as an expert partner for the pharmaceutical industry. Using our Ikonics® platform combined with our advanced statistics and clinical and therapeutic expertise, we provide insight-based decision-making solutions to optimise the clinical drug development trajectory.
Central imaging services
We manage and review clinical images centrally, ensuring consistency and efficiency across every trial stage.
Disease Characterisation
We uncover patterns to identify disease burden, subtypes, mutations and adverse events through quantitative biomarkers.
Response Evaluation
We track disease changes over time through imaging, to measure treatment impact.
Response Characterisation
Imaging helps us understand therapy response, by revealing the biological effects at play.
Outcome Prediction
We analyze imaging data to predict outcomes, helping guide clinical decisions with greater confidence.
Why radiomics.bio?
Experience
Creators of the term “radiomics,” our founders and scientists have been on the forefront of the developments of the technology and have unparalleled experience and international recognition in the field of AI.
Thought Leadership
The founders of radiomics.bio have seminal papers in Nature and are currently an active presenter in leading clinical research conferences in Europe and the US. Our management are recognised KOL and active members of scientific organisations relating to oncology research
Internationalism
radiomics.bio has partners and clients throughout the world including Europe, north America, Africa and Oceania. radiomics.bio has a permanent presence in North America with a fully owned affiliate in Toronto, Canada
Workforce
radiomics.bio is made up of a multidisciplinary and multicultural team. With a mix of experienced and enthusiastic scientists and technology experts, the team is always motivated to address client and partner needs.
Assets
radiomics.bio has an extensive IP portfolio, having secured seminal patents including the first prospective validated radiomic signature and delta analysis of radiomic features.
Client testimonials
See what our clients say about our services
*iOnctura has completed 3 projects with radiomics.bio
*iOnctura has completed 3 projects with radiomics.bio
How can radiomics help my clinical trial?
Radiomics facilitates objective decision-making in clinical trials. Radiomics allows you to make statistically informed decisions leading to the development of the most efficacious therapeutic and dose. With radiomics you can characterise disease, quantify dose impact, evaluate response, identify imaging biomarkers, predict response and more allowing for insight-based decision making.
Can radiomics reduce clinical risk?
Approximately 50% of clinical trials that fail, fail to demonstrate efficacy, with radiomics you can obtain insights during the early stages of treatment as well as predict which patients are most likely to respond. These insights can allow you to improve patient selection thus improving treatment efficacy, minimising the likelihood adverse events and reducing costs.
What insights can radiomics offer?
Radiomics provides a comprehensive profile of even the most complex or heterogenous response patients. In contrast to radiomics, biopsies are invasive, time consuming and expensive and only provide information/the genetic profile of the tumour from where the biopsy was extracted. Radiomics provides medically sound insights on lesion, organ and patient level, providing intra-patient heterogeneity even in highly metastatic patients.
How can radiomics help with patient stratification?
Patient stratification aims to tailor medical treatments to patients based on their own specific characteristics. Radiomics features total tumour burden and volumetric analyses provides comprehensive profiles of patients allowing you to stratify patients based quantitative imaging biomarkers and tumour morphology. This will allow you to different patients who are likely to respond from those who are resistant and select the best therapeutic option.
What can radiomic models predict?
Radiomic models have the potential to optimise clinical trials through the prediction of clinical outcomes, this includes prediction of individual lesion response patterns, patient survival likelihood at given time horizons and duration of progression free survival etc. These insights can optimise the trajectory of clinical trials allowing you to make objective decisions based on statistics.
What kind of medical images can radiomics be applied to?
Radiomics can be applied to MRI, CT and PET scans as well as their variations e.g. PET-CT
Learn more about the field of radiomics and how it can bring unprecedented insight into medical images
Discover More